Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Last trade$9.97
Day change+$0.11 (+1.12%)
Day range$9.69 – $10.22
Volume4,093,945
Market cap$1.38B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.38B
Price / earnings
—
Price / book
2.26×
Price / sales
26.17×
EV / sales
24.61×
EV / EBITDA
-3.06×
Profitability
Earnings per share
-$3.04
Return on assets
-47.21%
Return on equity
-69.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.12×
Current ratio
6.31×
Quick ratio
6.31×
Cash ratio
1.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$358.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NTLA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$7.16M
$7.66M
$15.05M
$23.02M
$13.78M
$14.25M
$16.63M
$12.87M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$7.16M
$7.66M
$15.05M
$23.02M
$13.78M
$14.25M
$16.63M
$12.87M
Selling, general and administrative
$46.14M
$37.82M
$34.84M
$33.08M
$30.51M
$27.21M
$29.01M
$32.44M
Research and development
$83.35M
$82.6M
$80.74M
$88.65M
$94.75M
$97.04M
$108.43M
$116.88M
Total operating expenses
$129.49M
$120.42M
$115.58M
$121.73M
$125.26M
$124.24M
$137.43M
$149.32M
Operating income
-$122.33M
-$112.76M
-$100.53M
-$98.71M
-$111.48M
-$110M
-$120.81M
-$136.45M
Interest expense
-$611K
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$127.49M
-$106.63M
-$96.23M
-$95.79M
-$101.32M
-$101.26M
-$114.33M
-$128.9M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$127.49M
-$106.63M
-$96.23M
-$95.79M
-$101.32M
-$101.26M
-$114.33M
-$128.9M
Net income attributable to common shareholders
-$127.49M
-$106.63M
-$96.23M
-$95.79M
-$101.32M
-$101.26M
-$114.33M
-$128.9M
EBITDA
-$120.4M
-$110.68M
-$98.33M
-$96.33M
-$109.06M
-$107.52M
-$118.31M
-$133.88M
Basic earnings per share
-$0.91
-$0.80
-$0.81
-$0.83
-$0.92
-$0.98
-$1.10
-$1.26
Diluted earnings per share
-$0.91
-$0.80
-$0.81
-$0.83
-$0.92
-$0.98
-$1.10
-$1.26
Recent news
Company coverage with links to the original publishers.
Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.
Intellia Therapeutics announced seven presentations at the ACAAI 2026 Annual Scientific Meeting featuring four-year follow-up data on lonvo-z, a one-time CRISPR gene editing treatment for hereditary angioedema (HAE). The company will host an investor webcast on November 12, 2026, to discuss the presentations and preparations for the planned commercial launch of lonvo-z. The FDA accepted the BLA for lonvo-z in September 2026 with a Priority Review and PDUFA target action date of March 10, 2027.
Biogen Inc. reported Q3 2026 earnings of $2.62 per share, beating consensus estimates by 27.18%, with revenues of $2.8 billion exceeding expectations by 8.06%. The stock has gained 43.6% year-to-date, outperforming the S&P 500. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. Intellia Therapeutics is expected to report a quarterly loss of $0.82 per share with declining revenues.
Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027. Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.
Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.